Key result
Pharmacist-led clinical interventions in a cardiac ICU yielded a 94% physician acceptance rate and a projected annual economic benefit of AU$13,534,013, resulting in a benefit-to-cost ratio of 50:1.
Why the study?
Do pharmacist-led clinical interventions improve economic outcomes and cost avoidance in a cardiac intensive care unit?
Observational
No
Do pharmacist-led clinical interventions improve economic outcomes and cost avoidance in a cardiac intensive care unit?
Pharmacist-led clinical interventions in a cardiac ICU demonstrate high physician acceptance and substantial cost savings, yielding a 50:1 benefit-to-cost ratio.
Background Pharmacists in intensive care units (ICUs) play a critical role in optimizing medication therapy and reducing adverse drug events (ADEs). While their clinical contributions are well recognized, data on their economic impact remain limited, particularly in Australian healthcare settings. Purpose This study aimed to evaluate the economic impact of pharmacist-led clinical interventions in a cardiac ICU by assessing physician acceptance rates, cost savings, cost avoidance, and overall financial benefits. Methods A retrospective analysis was conducted in a 16-bed cardiac ICU over 10 months (March 2023-December 2023. Pharmacist clinical interventions were extracted from the electronic medication chart and analyzed using Microsoft Excel. Cost savings were calculated by comparing the wholesale cost of initially prescribed medication versus intervened medication. Cost avoidance was estimated using the Nesbitt formula, assuming each prevented (ADE) would extend ICU stay by two days. The benefit-to-cost ratio (BCR) was determined by comparing total economic benefits to the annual salary of a clinical pharmacist. The hospital’s Human Research and Ethics Committee granted an exemption for this study. Results A total of 3,316 pharmacist clinical interventions were recorded, with a 94% physician acceptance rate. The economic analysis demonstrated annual cost savings of AU$26,273 and cost avoidance of AU$13,507,740 due to prevented ADEs. The projected total economic benefit over one year was AU$13,534,013 yielding a BCR of 50:1 indicating that every AU$1 invested in pharmacist salaries resulted in AU$50 in savings. These findings surpass previous international studies evaluating ICU pharmacist interventions, reinforcing their economical and clinical impact. Conclusion Pharmacist-led clinical interventions in the cardiac ICU significantly contribute to cost containment and improved patient safety. The high physician acceptance rate, substantial cost avoidance, and favourable BCR highlight the clinical and economic value of integrating pharmacist in ICU care. Future research should explore the scalability of these interventions across broader ICU settings.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2025) conducted an observational in Cardiac intensive care unit patients. Pharmacist-led clinical interventions was evaluated on Economic impact (cost savings, cost avoidance, and overall financial benefits). Pharmacist-led clinical interventions in a cardiac ICU yielded a 94% physician acceptance rate and a projected annual economic benefit of AU$13,534,013, resulting in a benefit-to-cost ratio of 50:1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: